Antares Pharma
Our Partners
For over 10 years Ferring has offered patients our needle free injector with their hGH product in Europe.
In 2009 Teva received FDA approval to market our needle free injector with their hGH product in the U.S. We have also partnered with Teva to develop injectors for four additional products.
Since 2004, JCR has offered patients our needle free injector in a campaign to broaden its marketing efforts for their hGH product.
In 2011 we partnered with Watson Pharmaceuticals to commercialize oxybutynin gel 3% (Anturol®) in the U.S. and Canada.
In 2012 we partnered with Daewoong Pharmaceuticals to commercialize oxybutynin gel 3% in South Korea.
We partnered with the Population Council to develop a nestorone /estradiol contraceptive product using ATD Gel.
Elestrin®, a hormone replacement product using our gel technology, received FDA approval in 2006 and is marketed by Azur Pharma.
In 2011 we partnered with Pfizer's Consumer Healthcare Business Unit to develop an undisclosed product based on one of our drug delivery technologies.